Systemic anaplastic large cell lymphoma (ALCL) is a subtype of peripheral Tcell lymphoma. It is divided into cases with and without translocation of the anaplastic lymphoma kinase gene (ALK), which most commonly involves chromosomes 2 and 5 and leads to ALK over-expression. Most patients with ALK translocations (ALK+) are potentially curable with doxorubicin-based chemotherapy, whereas patients without a translocation (ALK-) have a significantly lower survival. We tested dose-adjusted infusional etoposide, vincristine and doxorubicin with prednisone and cyclophosphamide (DA-EPOCH) in 24 patients with untreated ALK + (15) and ALK-(9) ALCL. The two groups had similar patient characteristics. At a median potential follow-up time of 14 years, the event free survival in ALK+ and ALK-ALCL was 72.0% and 62.5% (p=0.54), respectively, and the overall survival was 78.0% and 87.5% (p=0.83), respectively. DA-EPOCH had a favorable outcome in systemic ALCL and was independent of ALK status.
Anaplastic large cell lymphoma (ALCL) comprises around 6% of nonHodgkin's lymphomas. It is pathologically characterized by a broad morphological spectrum but usually contains large pleomorphic cells with strong CD30 expression and a cohesive growth pattern. ALCL is divided into systemic and cutaneous types based on clinical and immunophenotypic criteria. Furthermore, within systemic ALCL, there is biological heterogeneity in expression of the anaplastic lymphoma kinase (ALK) protein with positive cases usually harboring a translocation between the ALK gene on chromosome 2 and the nucleophosmin (NPM) gene chromosome 5, and ALK negative cases lacking a translocation The overall (OS) survival was calculated from on-study date until death or last follow-up and event-free survival (EFS) was calculated from on-study date until the date of progression, death or last follow-up using the Kaplan-Meier method. The significance of the difference between pairs of Kaplan-Meier curves was determined by the log-rank test. The median potential follow-up was calculated between the on-study date and April 1, 2015.
Twenty-four patients with newly diagnosed ALCL were enrolled (Table 1) .
Fifteen patients were ALK positive and 9 ALK negative according to ALK immunohistochemistry; the clinical characteristics of the 2 groups were similar. The median patient age was 38 years (range 19-68) and most patients were male (67%).
Indices of advanced disease included stage III or IV disease in 75% and an elevated lactate dehydrogenase in 50%. Fifty-four per cent of patients had extra-nodal disease and 25% of patients had peripheral blood or bone marrow involvement.
At a median potential follow-up of 14.4 years, ALK positive and negative patients had event free survival probabilities (EFS) of 72% (95% C.I. 45.9-88.6%) and 62.5% (95% C.I. 30.6-86.3%) (p=0.54) and overall survival probabilities (OS) of 78% (95% C.I. 51.0-92.3%) and 87.5% (95% C.I. 52.9-97.8%) (p=0.83), respectively ( Figure   1 ). Toxicity was assessed on all 141 cycles. The ANC pharmacodynamic target of less than 500 cells/mm 3 occurred on 35% of cycles and an ANC less than 100 cells/mm 3 on 17% of cycles. Thrombocytopenia < 25,000/mm 3 and fever and neutropenia occurred on 10% of cycles, respectively. Non-hematopoietic toxicities were similar to prior reports 12 .
While the outcome of ALK positive ALCL with anthracycline-based therapy is 5 . 6 . 8 . 
